Online citations, reference lists, and bibliographies.

Liver And Bone Metastases From Small Bowel Neuroendocrine Tumor Respond To 177Lu-DOTATATE Induction And Maintenance Therapies.

William Makis, Karey McCann, Francois A Buteau, A. J. Mcewan
Published 2015 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
A 73-year-old man diagnosed with small bowel neuroendocrine tumor (NET) with liver and bone metastases was treated with 4 induction cycles and 2 maintenance cycles of Lu-DOTATATE peptide receptor radionuclide therapy (PRRT). His symptoms and mobility improved significantly following induction as well as maintenance treatments, and posttherapy imaging studies showed significant improvement in metastatic liver and bone disease. Current protocols consisting of 4 induction cycles of Lu-DOTATATE only may not be sufficient to optimally treat neuroendocrine liver and bone metastases, and further research into maintenance Lu-DOTATATE therapy is warranted.
This paper references
Carcinoid metastasis to the brain. Cancer
R Hlatky (2004)
10.1007/s00259-010-1631-x
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
Phillip G. Claringbold (2010)
FFCDANGH-GERCOR: thirteenmonth registration of patients with gastroenteropancreatic endocrine tumours in France
C Lombard-Bohas (2009)
10.1159/000151562
Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France
Catherine Lombard-Bohas (2008)
10.1007/s00259-011-1835-8
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
Anna Sowa-Staszczak (2011)
10.1007/s00259-013-2369-z
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours
S. Severi (2013)
10.1089/cbr.2006.325
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
C. Wehrmann (2007)
10.1016/s0090-3671(08)70429-4
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
Thomas J. Fahey (2006)
10.1007/s00259-013-2402-2
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence
Davide Campana (2013)
10.1007/s00259-010-1610-2
Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
S. Ezziddin (2010)
FFCDANGH-GERCOR: thirteenmonth registration of patients with gastroenteropancreatic endocrine tumours
C Lombard-Bohas (2009)
10.1007/s002590050034
Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
Jean Claude Reubi (2000)
10.1007/s00259-011-2039-y
Lutetium-labelled peptides for therapy of neuroendocrine tumours
B. Kam (2011)
10.1200/JCO.2005.08.066
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
D. Kwekkeboom (2005)
10.1002/cncr.20659
Carcinoid metastasis to the brain.
R. Hlatký (2004)
10.1053/j.semnuclmed.2009.10.004
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
D. Kwekkeboom (2010)
[Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors)].
B. Kos-Kudła (2008)
Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism.
Wim G. Meijer (2003)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar